PLK1 and prostate carcinoma: We report that apigenin affects prostate cancer cells at G2 phase rather than at M phase with concomitant down-regulation of the regulators that govern G2-M transition at the transcriptional level including CDK1, CyclinB1, Polo-like kinase 1 (PLK1) and Aurora A [28].